A clinical study on the effect of Yinxing Damo combined with Betahistine Hydrochloride Injection on vertebral basilar artery ischemic vertigo

Deng Yan; Zhu Hai-qing; Deng Guo-bao; Tan Cheng

doi:10.1007/BF02836511

Your Location：

Home >

Browse articles >

A clinical study on the effect of Yinxing Damo combined with Betahistine Hydrochloride Injection on vertebral basilar artery ischemic vertigo

Updated：2021-08-27

- A clinical study on the effect of Yinxing Damo combined with Betahistine Hydrochloride Injection on vertebral basilar artery ischemic vertigo
- Chinese Journal of Integrative Medicine Vol. 11, Issue 3, Pages: 229-231(2005)
- Affiliations：
  
  Department of Neurology, The First People’s Hospital of Shaoguan,Guangdong
- Author bio：
- Funds：
- DOI：10.1007/BF02836511
  CLC：
- Published：2005，
Scan for full text
Yan, D., Hai-qing, Z., Guo-bao, D. et al. A clinical study on the effect of Yinxing Damo combined with Betahistine Hydrochloride Injection on vertebral basilar artery ischemic vertigo., Chin. J. Integr. Med. 11, 229–231 (2005). https://doi.org/10.1007/BF02836511

Deng Yan, Zhu Hai-qing, Deng Guo-bao, et al. A clinical study on the effect of Yinxing Damo combined with Betahistine Hydrochloride Injection on vertebral basilar artery ischemic vertigo. [J]. Chinese Journal of Integrative Medicine 11(3):229-231(2005)
Yan, D., Hai-qing, Z., Guo-bao, D. et al. A clinical study on the effect of Yinxing Damo combined with Betahistine Hydrochloride Injection on vertebral basilar artery ischemic vertigo., Chin. J. Integr. Med. 11, 229–231 (2005). https://doi.org/10.1007/BF02836511 DOI：

Deng Yan, Zhu Hai-qing, Deng Guo-bao, et al. A clinical study on the effect of Yinxing Damo combined with Betahistine Hydrochloride Injection on vertebral basilar artery ischemic vertigo. [J]. Chinese Journal of Integrative Medicine 11(3):229-231(2005) DOI： 10.1007/BF02836511.

摘要

Objective: To evaluate the therapeutic efficacy of Yinxing Damo (YXDM) combined with Betahistine Hydrochloride Injection (BHI) on vertebra basilar artery ischemic vertigo (VBIV).Methods: Ninety patients with VBIV were randomly divided into two groups; 45 patients (the treated group) were treated with YXDM and BHI intravenous dripping

once a day for 14 days. Another 45 patients (control group) were treated with Xueshuantong and BHI intravenous dripping

once daily for 14 days. The clinical syndromes and the index of the transcranial Doppier (TCD) and hemorheology were observed.Results: The total effective rate was 100% in the treated group

which was better than that in the control group 90.5%

(P<0.05). The indexes of TCD and hemorheology in the treated group were obviously improved after treatment

(P<0.01).Conclusion: YXDM combined with BHT injection had better effect in treating patients with VBIV is an ideal drug for VBIV.

Abstract

once a day for 14 days. Another 45 patients (control group) were treated with Xueshuantong and BHI intravenous dripping

once daily for 14 days. The clinical syndromes and the index of the transcranial Doppier (TCD) and hemorheology were observed.Results: The total effective rate was 100% in the treated group

which was better than that in the control group 90.5%

(P<0.05). The indexes of TCD and hemorheology in the treated group were obviously improved after treatment

(P<0.01).Conclusion: YXDM combined with BHT injection had better effect in treating patients with VBIV is an ideal drug for VBIV.

关键词

Yinxing DamoBetahistine hydrochloride injectionvertebra basilar artery ischemiavertigo

Keywords

Yinxing DamoBetahistine hydrochloride injectionvertebra basilar artery ischemiavertigo

references

Huang RX, Liang XL, Liu ZL, chief editors. Clinical neurology. Beijing: People’s Medical Publishing House, 1996: 225.

Pu CfQ, Lang SY, Wu WP, chief editors. Cerebral vascular diseases. Beijing: People’s Military Medical Medicine, 1999: 275.

Lenoir M, Pedruzzi E, Rais S. Sensitization of human neutrophil defence activities through activation of platelet activating receptors by ginkgolide B, a bioactive component of the Ginkgo biloba extract EGB 761. Biochem Pharmacol 2002;63 (7): 1241–1249.

Closure F. Gingko biloba extract (EGB761), state of knowledge in the dawn of the year 2000. Ann Pharm Fr 1999; 57 (1): 158–188.

FULL TEXT LINK

More>

Views

392

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Study on Yangxue Qingnao granule in treating chronic cerebrovascular insufficiency

Related Author

No data

Related Institution

Zhongshan Hospital Affiliated to Fudan University

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰